

VPA10521/012/001

Drontal Dog Tasty Bone 150/144/50 mg tablets

Variation	Summary	Date
Vet - A1 b)	VNRA - Vet - A1 b) - b) Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier. - A1 b) Administratvie changes: Change in the name or address or contact details of a manufacturer or supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance or a quality control testing site (where ecified in the dossier) where no European Pharmacopoeia (Ph. Eur.) Certificate of Suitability (CEP) is part of the approved dossier.	26/03/25
Vet - B4 c)	VNRA - Vet - B4 c) - c) Introduction of a new site of micronisation for the manufacturer of the active substance (including relevant quality control testing sites) - B4 c) Changes to the quality part of the dossier: Changes to the production process or the storage of active substance where no Ph. Eur. CEP is part of the approved dossier of an active substance (including starting material, reagent or intermediate) - introduction of a new site of micronisation for the manufacturer of the active substance (including relevant quality control testing sites)	25/03/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	20/06/24
Vet - F.I.f.1	VRA-S - Vet - F.I.f.1 - 1. Substantial changes in the updated version of the ASMF or the active substance part of the dossier - F.I.f.1 Quality Changes - Active Substance - Other changes to the active substance - Substantial changes in the updated version of the ASMF or the active substance part of the dossier	14/05/24
Vet - B11 b)	VNRA - Vet - B11 b) - b) Tightening of specification limits of an active substance, starting material, intermediate or reagent used	22/03/24

	in the manufacturing process of the active substance - B11 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance or of the immediate packaging of the active substance — tightening of specification limits of an active substance, starting material, intermediate or reagent used in the manufacturing process of the active substance	
Vet - B3 n)	VNRA - Vet - B3 n) - n) Deletion of a non-significant specification parameter (finished product) - B3 n) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) in the specification parameters or limits of the finished product	22/03/24
Vet - B4 c)	VNRA - Vet - B4 c) - c) Introduction of a new site of micronisation for the manufacturer of the active substance (including relevant quality control testing sites) - B4 c) Changes to the quality part of the dossier: Changes to the production process or the storage of active substance where no Ph. Eur. CEP is part of the approved dossier of an active substance (including starting material, reagent or intermediate) - introduction of a new site of micronisation for the manufacturer of the active substance (including relevant quality control testing sites)	22/03/24
Vet - B12 a)	VNRA - Vet - B12 a) - a) Minor changes to an approved test procedure (active, finished product, packaging, measuring device) - B12 a) Changes to the quality part of the dossier: Minor changes — to an approved test procedure — for active substance; — for the finished product; —for the immediate packaging of the active substance or the finished product; — of a measuring or administration device	22/03/24
Vet - B20	VNRA - Vet - B20 - Replacement or addition of a primary packaging site of a non-sterile finished product - B20 Changes to the quality part of the dossier: Replacement or addition of a primary packaging site of a non-sterile finished product	22/03/24
Vet - B21	VNRA - Vet - B21 - Replacement or addition of a secondary packaging site of a finished product - B21 Changes to the quality part of the dossier: Replacement or addition of a secondary packaging site of a finished product	22/03/24
Vet - B35 b)	VNRA - Vet - B35 b) - b) Addition of a new specification parameter to the specification with its corresponding test method - B35 b) Changes to the quality part of the dossier: Change in the specification parameters or limits of the immediate packaging of the finished product: — addition of a new specification parameter to the specification with its corresponding test method	22/03/24
Vet - B36	VNRA - Vet - B36 - Change in test procedure for the immediate packaging of the finished product (including replacement or addition) - B36 Changes to the quality part of the dossier: Change in test procedure for the immediate packaging of the finished product (including replacement or addition)	22/03/24

Vet – B24 a)	VNRA - Vet – B24 a) - B24 Replacement or addition of a manufacturer responsible for a) - B24 Replacement or addition of a manufacturer responsible for a)- batch release including batch control or testing of a sterile or non-sterile finished product	22/03/24
Vet - B3 n)	VNRA - Vet - B3 n) - n) Deletion of a non-significant specification parameter (finished product) - B3 n) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) in the specification parameters or limits of the finished product	22/03/24
Vet - B3 n)	VNRA - Vet - B3 n) - n) Deletion of a non-significant specification parameter (finished product) - B3 n) Changes to the quality part of the dossier: Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter such as odour and taste or identification test for a colouring or flavouring material) in the specification parameters or limits of the finished product	22/03/24
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing process - F.II.b.3 a) Quality Changes - Finished Product -Manufacture - Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - Minor change in the manufacturing process	22/03/24
Vet - F.I.b.2 b)	VRA-R - Vet - F.I.b.2 b) - b) Other changes to a test procedure (including replacement or addition) for the active substance - F.I.b.2 b) Quality Changes - Active Substance - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance	22/03/24
Vet - F.I.b.2 b)	VRA-R - Vet - F.I.b.2 b) - b) Other changes to a test procedure (including replacement or addition) for the active substance - F.I.b.2 b) Quality Changes - Active Substance - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance	22/03/24
Vet - F.I.b.2 b)	VRA-R - Vet - F.I.b.2 b) - b) Other changes to a test procedure (including replacement or addition) for the active substance - F.I.b.2 b) Quality Changes - Active Substance - Control of active substance - Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - Other changes to a test procedure (including replacement or addition) for the active substance	22/03/24
Vet - F.I.b.1 z)	VRA-R - Vet - F.I.b.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of	22/03/24

	EMA/CMDv/7381/2021 - F.I.b.1 z) Quality Changes - Active Substance - Control of active substance -Change in the specification parameters and/or limits of an active substance, starting material/intermediate/reagent used in the manufacturing process of the active substance - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.II.b.1 c)	VRA-R - Vet - F.II.b.1 c) - c) Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products - F.II.b.1 c) Quality Changes - Finished Product -Manufacture - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products	22/03/24
Vet - B3 t)	VNRA - Vet - B3 t) - t) Deletion of a Ph. Eur. CEP - B3 t) Changes to the quality part of the dossier: Deletion of a Ph. Eur. CEP — for an active substance; — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient	16/02/24
Vet - B3 t)	VNRA - Vet - B3 t) - t) Deletion of a Ph. Eur. CEP - B3 t) Changes to the quality part of the dossier: Deletion of a Ph. Eur. CEP — for an active substance; — for a starting material, reagent or intermediate used in the manufacturing process of the active substance; — for an excipient	16/02/24
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	16/06/23
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	16/06/23
C.I.z	IB - C.I.z - z Other variation - C.I.z - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - HUMAN AND VETERINARY MEDICINAL PRODUCTS - Other variation	29/03/22